60 F
New York
Friday, May 7, 2021

Tiziana [NASDAQ: TLSA] Submits Patent Application For Use Of Foralumab In COVID-19

Must read

Coinbase Pro Announces it will be Listing Internet Computer’s ICP

Coinbase Pro cryptocurrency exchange has disclosed that it has decided to list ICP once it goes live. ICP is the governance token of the...

WISeKey [NASDAQ: WKEY] Gets Investment to finance its TrustNFT.IO NFT Platform

WISeKey International Holding AG disclosed Friday that it has inked a term-sheet to enter into an unsecured short-term loan and the issuance and...

Moderna [NASDAQ: MRNA] Inks Supply Agreement with Switzerland

Moderna, Inc. disclosed that it has inked a supply agreement on Thursday with the Swiss Federal Government. As per the agreement, Moderna Inc...

TeraBlock Will Have its Own BSCPad IDO Soon

TeraBlock which is a project making a platform for automated cryptocurrency portfolio management disclosed that it is preparing for an initial DEX offering (IDO)...

Tiziana Life Sciences PLC [NASDAQ: TLSA] disclosed today it has submitted an application for the use of Foralumab in the treatment of COVID-19. The combination of anti-viral & anti-inflammatory drugs proven to be very useful in the treatment of COVID-19 patients at different stages, recent clinical studies suggested.

Foralumab is known as NI-0401 is a fully-human monoclonal anti-CD3 antibody which is developed for the treatment of autoimmune & inflammatory diseases.

Foralumab nasal administration has the potential to improve the immune system. It also has the ability to put down the cytokines storm and decrease respiratory failure in COVID-19 patients. Foralumab nasal administration when combined with other anti-viral drugs plays an important role in improving treatment efficacy.

Shares of Tiziana soared 19.06% at $12.37 during the trading of Thursday. It had trading volume of 1.6 million as compared to the average volume of 305.68K. Tiziana has total market capitalization of 411.70 million.

In the past 52-weeks of trading, this company’s stocks have fluctuated between the low of $1.54 and a high of $12.61. It has moved up 703.25% from 52-weeks low and moved down -1.90% from its 52-weeks high.

A biotechnology company has a worldwide license for the nasal administration of Foralumab and other anti CD3 mAbs for the treatment of various diseases. Earlier, Tiziana has developed the nasal spray device using Foralumab. The firm has also disclosed the successful completion Phase 1 trial with the oral administration of Foralumab.

More articles

Latest article

Why Chiasma [NASDAQ: CHMA] Stock is Skyrocketed?

Shares of Chiasma, Inc. surged 46.48% during the trading session of Wednesday. Chiasma has disclosed the financial results for the Q1 completed March...

NeoGenomics [NASDAQ: NEO] Announces Acquisition of Inivata Ltd

NeoGenomics, Inc. revealed Wednesday that it has decided to purchase Inivata Ltd. Inivata will grow into a liquid biopsy-centered division together with increasing...

R1 RCM [NASDAQ: RCM] Announces Acquisition of VisitPay

R1 RCM Inc. disclosed Tuesday that it has decided to purchase VisitPay. The firm has inked an agreement to buy VisitPay for nearly...

Binance Coin Makes History as its Market Cap Reach $100 Billion

The market capitalization of Binance set new records as the exchange token of Binance and the native asset of Binance Smart Chain (BSC) touched...

Precipio [NASDAQ: PRPO] Roll Out Rapid COVID-19 Antibody test on Amazon Platform

Shares of Precipio, Inc. skyrocketed 40.35% during the trading session of Monday. The strong performance of the firm has highlighted the positive sentiments...

TechX Ink Deal to Buy Fiat-to-Crypto Merchant Services Gateway XPort Digital

TechX Technologies Inc disclosed Monday that it has bought fiat-to-crypto merchant services gateway XPort digital. The firm has bought a 100% stake in XPort...

Lockheed [NYSE: LMT] Present F-35 Best and Final Offer to Finnish Government

Lockheed Martin Corporation disclosed that it has presented F-35 best and final offer (BAFO) on April 29, 2021, to the Finnish government. It...

Clene [NASDAQ: CLNN] Gets Two Patent Notice of Allowances

Clene Inc. disclosed that Clene Nanomedicine, Inc. U.S. Patent and Trademark Office has provided Notices of Allowance for two significant patent applications. Clene...